N/A N=25 A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis
Leukemia · Amyloidosis
Primary: Hematologic Response Rate — 2; 4; 8; 9 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=57 A Phase 2 Trial of MLN8237 in Adult Participants With Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome
Acute Myelogenous Leukemia · High-Grade Myelodysplastic Syndrome
Primary: Best Overall Response Rate (ORR) Based on Investigator's Assessment — 6; 0; 1; 0 participants
N/A N=589 Latin American Real-world Study in Acute Leukemia
Acute Myeloid Leukemia · Acute Lymphoid Leukemia
Primary: Number of Participants According to Health Insurance Type — 265; 44; 253; 27 Participants
Phase 2 N=52 AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia
Leukemia, Myeloid, Acute
Primary: Phase I Only: Optimal Dose of AMD3100 Plus MEC in Patients With Relapsed or Refractory AML — 240 mcg/kg
Phase 2 N=42 Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML
Acute Myeloid Leukemia
Primary: Number of Participants That Achieved Complete Remission — 20 Participants
Phase 2 N=7 Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)
Leukemia, Myeloid, Acute
Primary: Dose-limiting Toxicity — 0; 0 Participants
Phase 2 N=47 Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin
Stem Cell Transplantation · Leukemia
Primary: Number of Participants With Grade 4 Dose Limiting Toxicity to Determine Maximum Tolerated Dose (MTD) Plerixafor — 1; 4; 7; 4 participants
Phase 2 N=148 A Safety and Efficacy Study of Eltrombopag in Subjects With AML
Acute Leukaemia
Primary: Number of Participants With Any Adverse Events (AE) and Any Serious Adverse Events (SAE) as a Measure of Safety and Tolerability. — 72; 66; 24; 14 Participants
Phase 2 N=27 A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis
AL Amyloidosis
Primary: Assessing Dose-limiting Toxicity to Determine Maximal Tolerated Dosage at 2 Milligram Dose — 0 Participants
Phase 2 N=37 Methotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage
Leukemia, Lymphocytic, Acute
Primary: Complete Response (CR) Rate — 28 percentage of participants
Phase 2 N=32 Nebulized Amphotericin B Lipid Complex in Invasive Pulmonary Aspergillosis in Paediatric Patients With Acute Leukaemia
Invasive Pulmonary Aspergillosis · Lymphoblastic Leukaemia · Myeloblastic Leukaemia
Primary: Number of Participants With Adverse Events That Results in the Interruption of Treatment, as a Measure of Safety and Tolerability — 0 participants
Phase 3 N=89 Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Hematologic Response Rate — 55.9; 69.1 percentage of participants
Phase 3 N=335 Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients
B-Cell Chronic Lymphocytic Leukemia
Primary: Kaplan-Meier Estimates for Progression-free Survival (PFS) Based on Independent Response Review Panel (IRRP) Assessment — 23.65; 16.48 months — p=<0.001
Phase 2 N=12 AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)
Acute Myeloid Leukemia (AML) · Myelodysplastic Syndrome
Primary: Percentage of Participants With Objective Response (OR) — 0 Percentage of participants
Phase 2 N=20 Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant
Acute Myeloid Leukemia
Primary: Number of Patients With 2-year Relapse Risk — 10 Participants
N/A N=26 Low Dose Melphalan and Bortezomib for AML and High-Risk MDS
Acute Myelogenous Leukemia · Myelodysplastic Syndromes
Primary: Response Rate of the Combination of Bortezomib and Melphalan in Patients With AML and High-risk MDS. — 5; 2 participants
Phase 2 N=22 17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma
Anaplastic Large Cell Lymphoma · Recurrent Adult Hodgkin Lymphoma · Recurrent Mantle Cell Lymphoma
Primary: Number of Patients With Response — 0; 2 participants
Phase 1 N=27 Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis
Light-Chain Amyloidosis
Primary: Number of Participants With at Least One Treatment Emergent Adverse Event (TEAE) and Serious Adverse Event (SAE) — 6; 5; 5; 10 Participants
Phase 1 N=32 Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).
Acute Myeloid Leukemia
Primary: Maximum Tolerated Dose (MTD) of Alvocidib — 30; 60 mg/m2
Phase 2 N=20 Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT
Acute Myelogenous Leukemia (AML) · Myelodysplastic Syndrome (MDS)
Primary: Incidence of Relapse — 30 Percentage of participants
Phase 2 N=82 Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies
Advanced Hematologic Malignancies · Leukemia · Preleukemia
Primary: Number of Participants With Hepatic Adverse Events During the Conditioning Regimen Prior to Stem Cell Transplantation — 48; 30 participants
Phase 2 N=129 The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis
AL Amyloidosis
Primary: Number of Participants With Cardiac Response and Non-Response — 26; 30; 40; 33 Participants — p=0.3190
Phase 3 N=657 Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia
Leukemia
Primary: Overall Survival (Induction Phase) — 15.7; 23.7 months
Phase 2 N=195 Study of Temozolomide in Previously Untreated Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Participants With Low O6-Methylguanine Methyltransferase (MGMT) Expression (P05052)
Leukemia, Acute Myeloid · Myelodysplastic Syndrome
Primary: Clinical Response at the End of Temozolomide Induction — 10; 2; 4; 8 participants
Phase 2 N=46 Prospective Study of Mylotarg and G-CSF in Acute Myeloid Leukemia Treatment
Novo Acute Myeloid Leukemia
Primary: Complete Remission of the Disease — NA; 18; 16; NA Participants
Phase 2 N=16 Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
Multiple Myeloma
Primary: Number of Participants With Hematologic Response — 7 participants
Phase 2 N=384 Allo vs Hypomethylating/Best Supportive Care in MDS (BMTCTN1102)
MDS
Primary: Percentage of Participants With Overall Survival (OS) — 47.9; 26.6 percentage of participants — p=0.0001
Phase 2 N=60 ALS Reversals - Lunasin Regimen
ALS (Amyotrophic Lateral Sclerosis)
Primary: Change in Revised ALS Functional Rating Scale (ALSFRS-R) — 0.44 points per month — p=0.99
Phase 2 N=4 Lenalidomide in HTLV-1 Adult T-Cell Leukemia
Adult T Cell Leukemia/Lymphoma
Primary: Response Rate (CR + Cru + PR)
Phase 2 N=73 Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia
Adult Acute Myeloid Leukemia · Secondary Acute Myeloid Leukemia · Therapy-Related Acute Myeloid Leukemia
Primary: Rate of Complete Remission and Mortality in the Entire Cohort of Older Patients — 21.9; 52.0 percentage of subjects